| WB | 1/500-1/2000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | ATDC |
| WB Predicted band size | 66 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human TRIM29 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇涉及TRIM29抗体的研究文献概览(基于公开研究数据模拟，非真实文献)：
1. **文献名称**：TRIM29 promotes bladder cancer invasion through regulation of EMT markers
**作者**：Li X, et al.
**摘要**：该研究利用TRIM29抗体进行免疫组化分析，发现TRIM29在膀胱癌中高表达，并通过激活Wnt/β-catenin通路促进上皮-间质转化(EMT)，导致肿瘤侵袭性增强。
2. **文献名称**：Role of TRIM29 in pancreatic cancer progression and its interaction with p53
**作者**：Wang Y, et al.
**摘要**：通过Western blot和免疫荧光技术(使用TRIM29特异性抗体)，证实TRIM29在胰腺癌中与p53蛋白相互作用，抑制其稳定性，进而促进肿瘤细胞增殖和化疗耐药。
3. **文献名称**：TRIM29 as a potential biomarker in triple-negative breast cancer
**作者**：Chen H, et al.
**摘要**：研究采用TRIM29抗体对乳腺癌组织进行染色，发现TRIM29在三阴性乳腺癌中显著高表达，且与患者预后不良相关，提示其可作为治疗靶点或诊断标志物。
如需具体文献，建议通过PubMed或Web of Science以“TRIM29 antibody”为关键词检索最新研究。
TRIM29 (Tripartite Motif-containing protein 29), also known as ATDC (Ataxia-Telangiectasia Group D Complementing), is a member of the TRIM protein family characterized by conserved zinc-binding domains. It plays diverse roles in cellular processes, including DNA damage repair, cell proliferation, apoptosis, and immune regulation. TRIM29 lacks a canonical RING domain but contains B-box and coiled-coil motifs, which mediate protein interactions and subcellular localization. Its expression is tissue-specific, with high levels observed in epithelial tissues, and dysregulation has been implicated in cancer progression, showing both tumor-suppressive and oncogenic functions depending on context. For instance, TRIM29 is overexpressed in pancreatic, bladder, and lung cancers, promoting invasiveness and chemoresistance, while acting as a tumor suppressor in breast and colorectal cancers.
TRIM29 antibodies are essential tools for detecting and quantifying TRIM29 protein expression in research and diagnostics. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to study TRIM29's localization, interactions, and roles in disease mechanisms. Commercially available antibodies are typically raised against specific epitopes, such as the N-terminal or C-terminal regions, and require validation for cross-reactivity and specificity. Studies utilizing these antibodies have linked TRIM29 to pathways like NF-κB signaling, p53 regulation, and Wnt/β-catenin signaling. Its dual role in cancer and association with poor prognosis in certain malignancies make TRIM29 a potential therapeutic target, with antibodies aiding in biomarker discovery and mechanistic studies.
×
